The administration of dexmedetomidine could improve postoperative cognitive dysfunction, emergence agitation, depression and anxiety, attenuate the plasma concentrations of S-100β and NSE and reduce the dosage of etomidate and remifentanil administered during the operation. This evidence concerns the gene ENO2 and major depressive disorder.